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NEURODEVELOPMENTAL OUTCOMES OF DUARTE GALACTOSEMIA: 
 
AN EXPLORATION OF COGNITIVE DEVELOPMENT AND SPECIAL 
 
NEEDS IN DUARTE GALACTOSEMIA PATIENTS 
 
CATHERINE T. TRAN 
 
ABSTRACT 
 Duarte galactosemia is a variant form of galactosemia that on average 
results in a reduction of the galactose-1-phosphate uridyltransferase enzyme to 
25% activity. This enzyme is involved in the metabolism of galactose in the body. 
On the contrary, patients diagnosed with the classic form of galactosemia have a 
galactose-1-phosphate uridyltransferase enzyme activity of zero or near-zero. As 
a result, classic galactosemics are placed on galactose-restricted diets to prevent 
acute neonatal signs of disease that can ultimately lead to death. These diets are 
instituted for the rest of the patients’ lives. However, even with dietary treatment, 
classic galactosemia patients go on to experience long-term neurodevelopmental 
outcomes, most notably cognitive defects and speech and language delay. 
Duarte galactosemia patients, as a result of their residual enzyme activity, 
experience much milder disease symptoms. Many specialists agree that these 
patients have a benign disease and therefore treatment is not consistently 
agreed upon nor prescribed. Most Duarte patients follow an unrestricted diet and 
if a diet is prescribed, it is only for the first year of life. While these patients have 
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enough enzyme activity to prevent acute neonatal signs of disease, there is still 
limited information regarding any long-term neurodevelopmental outcomes in the 
Duarte galactosemia population.  
This study examined developmental outcomes and need for special 
services of a sample of Duarte galactosemia patients. The outcome data were 
compared to the general population as well as to a classic galactosemia group. A 
convenience cohort of clinical charts for patients seen for neuropsychological 
evaluations from 1978 to 2013 was reviewed. Developmental scores, 
neuropsychological outcomes, and need for special services for patients 
diagnosed with a form of galactosemia were entered into an electronic database. 
Recorded developmental information on twenty-two Duarte galactosemia 
patients were found. All of the 22 Duarte patients were found to have 
developmental test scores within normal range. However, 38.9% of Duarte 
patients containing information regarding special services were found to 
participate in early intervention, 71.4% of which received speech therapy. 
Furthermore, 22.2% of Duarte patients containing information regarding special 
services were found to participate in special education, and 100% of these 
children received speech therapy.  
In conclusion, despite Duarte galactosemia patients not exhibiting lower 
learning test scores, there was a large proportion of them participating in special 
services, particularly in speech therapy. This indicates some speech and 
language difficulties in children with Duarte galactosemia.   
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INTRODUCTION 
 
 
What Is Galactosemia? 
 Galactosemia is a disorder in which there is a disruption in how the body 
processes galactose (Louis J Elsas, 1993; “Galactosemia - Genetics Home 
Reference,” 2008). Patients with this rare genetic disorder have an impaired 
ability to utilize galactose from their diet (Berry & Walter, 2012). The primary 
pathway of galactose metabolism is known as the Leloir pathway (Fridovich-Keil 
& Walter, 2013). The Leloir pathway involves 3 main enzymes: galactokinase 
(GALK), uridine diphosphate galactose-4’-epimerase (GALE), and galactose-1-
phosphate uridyltransferase (GALT). Impairment in any of the important enzymes 
in the Leloir pathway can result in a form of galactosemia (Fridovich-Keil & 
Walter, 2013) 
Galactose is a part of the disaccharide lactose which is found 
predominantly in milk (Berry & Walter, 2012; Fridovich-Keil & Walter, 2013).  
Ingested lactose is broken down in the intestine to galactose and glucose and 
these monosaccharides are then absorbed. Once galactose has been absorbed, 
it can be further converted into glucose-1-phosphate and subsequently be used 
as an energy source. Thus, particularly in infants where milk is the primary food 
source, galactose is an essential nutrient (Berry & Walter, 2012; Fridovich-Keil & 
Walter, 2013). 
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Classic Galactosemia 
The most profound form of galactosemia is described as classic 
galactosemia and is caused by severe galactose-1-phosphate uridyltransferase 
(GALT) deficiency (Berry & Walter, 2012; Louis J Elsas, 1993; Fridovich-Keil & 
Walter, 2013) Currently, there are 266 recorded GALT gene mutations that result 
in various forms of enzyme deficiency and consequently different severities of the 
disorder. Of the recorded mutations however, 85% are known to be pathogenic 
and associated with classic galactosemia (Calderon, Phansalkar, Crockett, Miller, 
& Mao, 2007). The biochemical consequences of the pathogenic GALT 
deficiency are abnormal accumulations of galactose and its metabolites such as 
galactose-1-phosphate (gal-1-P), galactitol, and galactonate in the blood, tissues, 
and urine of patients (Berry & Walter, 2012; Louis J Elsas, 1993; Fridovich-Keil & 
Walter, 2013)  
Classic galactosemia occurs in about 1 in every 40,000-60,000 births in 
the United States and is detected by newborn screening (Berry & Walter, 2012; 
Louis J Elsas, 1993). The inheritance pattern for classic galactosemia is 
described as autosomal recessive where both copies of the gene in each cell of 
the child must have the mutation. As an inherited genetic disease, classic 
galactosemia is passed down among families (Berry & Walter, 2012; Louis J 
Elsas, 1993; “Galactosemia - Genetics Home Reference,” 2008). However, 
parents of galactosemic children each carry one copy of the autosomal recessive 
gene with a normal gene and generally do not manifest any symptoms 
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associated with the disorder (Louis J Elsas, 1993; “Galactosemia - Genetics 
Home Reference,” 2008).  
In places where newborn screening is not available or does not include 
screening for galactosemia, physicians must remain vigilant towards newborns 
presenting with clinical symptoms of galactosemia. Infants with classic 
galactosemia have zero or barely detectable GALT enzyme activity (Berry & 
Walter, 2012; Louis J Elsas, 1993). Thus, classic galactosemia is a medical 
emergency in the newborn infant as it can result in life-threatening signs of 
disease after the exposure to lactose (Berry & Walter, 2012; Louis J Elsas, 1993; 
Fridovich-Keil & Walter, 2013). At birth, these infants present with normal weight, 
but as they begin consuming milk, acute symptoms of the disorder can manifest 
in the first days of life. These symptoms include failure to thrive, trouble feeding, 
vomiting, jaundice, and lethargy. Damage of the liver and kidney, bleeding, 
cataracts, and bacterial infections can follow, ultimately leading to death if left 
untreated. If a galactose disorder is suspected, milk-feeding should be stopped 
immediately (Berry & Walter, 2012; Louis J Elsas, 1993; Fridovich-Keil & Walter, 
2013).  
Once classic galactosemia is confirmed, the dietary therapy remains with 
a diet restricted from galactose and ultimately lactose. Typically, there is an 
exception to fruits and vegetables that contain small amounts of galactose and 
those foods are often allowed in the diet (Berry & Walter, 2012). With this 
treatment, the detrimental symptoms in early infancy can rapidly resolve and the 
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further complications of liver problems, bacterial infections, and death can be 
prevented. This galactose-restricted diet is instituted for the rest of the patient’s 
life (Berry & Walter, 2012; Louis J Elsas, 1993; Fridovich-Keil & Walter, 2013; 
Waisbren, Norman, Schnell, & Levy, 1983).  
The majority of patients with classic galactosemia, even with prompt 
treatment, still experience life-long complications as they develop and grow 
(Berry & Walter, 2012; Louis J Elsas, 1993; Fridovich-Keil & Walter, 2013). While 
complications in intellectual development and growth are much more likely if 
treatment is delayed, infants with classic galactosemia remain at risk for further 
long-term complications. Generally, these long-term outcomes include 
developmental delays, speech deficits, fine motor function problems, cataracts, 
poor growth, and overall intellectual disabilities (Berry & Walter, 2012; Louis J 
Elsas, 1993; Fridovich-Keil & Walter, 2013). Females with classic galactosemia 
are also at a greater risk for primary ovarian insufficiency (POI) and overall 
ovarian dysfunction (Berry & Walter, 2012; Fridovich-Keil et al., 2011).  
 
Duarte Galactosemia: A Variant Form 
With the numerous gene mutations of the GALT enzyme that exist, not all 
of them transpire into a classic galactosemia diagnosis. Duarte galactosemia is a 
disorder resulting from a variant form of GALT deficiency (Berry & Walter, 2012; 
Fridovich-Keil & Walter, 2013). The Duarte variant of galactosemia presents with 
milder clinical outcomes and is in fact the most frequent variant of GALT mutation 
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(Berry & Walter, 2012; Fernhoff, 2010; Ficicioglu et al., 2008; Fridovich-Keil & 
Walter, 2013). It is most commonly found in newborn screening because of 
moderately elevated amounts of blood galactose and lower, but not zero, GALT 
activity (Berry & Walter, 2012).  
Despite the abnormality of the GALT enzyme, patients with the Duarte 
gene, even if paired with the classic galactosemia gene, are usually healthy. 
These patients with one Duarte gene and one classic galactosemia gene, 
commonly referred to as D/G patients, retain about 25% of normal GALT enzyme 
activity (Berry & Walter, 2012; Louis J Elsas, 1993; Fernhoff, 2010; Ficicioglu et 
al., 2008; Fridovich-Keil & Walter, 2013). With just 25% of enzyme activity, D/G 
patients seem to remain without clinical symptoms, especially the acute 
symptoms characteristic of classic galactosemia (Berry & Walter, 2012; Ficicioglu 
et al., 2008; Fridovich-Keil & Walter, 2013).  
Currently, there is no general consensus as to whether or not Duarte 
galactosemia patients should be treated via diet-therapy (Berry & Walter, 2012; 
Louis J Elsas, 1993; Fridovich-Keil & Walter, 2013). Even though the majority of 
D/G patients often present without classic galactosemia symptoms, infants can 
accumulate some mild to moderately elevated levels of galactose metabolites 
early in life, particularly red blood cell gal-1-P from ingesting lactose (Fernhoff, 
2010). Along with the elevated gal-1-P levels, other metabolites like galactitol, 
galactonate, and urine galactitol also show higher values during early infancy 
(Ficicioglu et al., 2008). Thus, some medical facilities and centers have instituted 
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a practical treatment plan towards Duarte patients. This plan starts with a 
galactose-restricted diet, as that prescribed to classic galactosemia patients, in 
the first 1 to 4 months of life, and is then followed by a transition to a galactose-
containing diet as the blood gal-1-P levels normalize (Berry & Walter, 2012). 
Other centers, however, choose to maintain a galactose-restricted diet through 
the first year of life until the gal-1-P levels normalize (Berry & Walter, 2012; 
Fernhoff, 2010). Still, there are many facilities where no dietary treatment is 
prescribed to Duarte galactosemia patients at all (Fridovich-Keil & Walter, 2013). 
Long-term complications of Duarte galactosemia in older children and 
adults have been reported only minimally (Badik et al., 2011; Powell et al., 2009). 
Since treatment varies across the United States, Duarte patients are often lost to 
follow-up once they enter early childhood, whether or not they were on treatment 
(Badik et al., 2011; Fernhoff, 2010). Unlike the known long-term outcomes in 
classic galactosemia, there is no consensus regarding the complications that 
may be experienced in Duarte galactosemia. Thus, the questions of any long-
term complications in this group are still left unanswered (Badik et al., 2011; 
Fernhoff, 2010). In regards to another long-term outcome comparable to classic 
galactosemia, female reproductive problems, Badik et al (2011) has studied 
ovarian function in Duarte galactosemia. All of their 57 female D/G patients were 
found not to have any increased risk for premature ovarian insufficiency, a stark 
difference from the known complication of POI in female classic galactosemia 
patients (Badik et al., 2011). 
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Genetics and Testing of Classic and Duarte Galactosemia 
 The most common genotype for classic galactosemia that presents with 
severe outcomes of the disease is a homozygous Q188R mutation, where an 
arginine is substituted for a glutamine at the amino acid position 188. As a result, 
the catalytic activity of the GALT enzyme complex is absent or greatly reduced 
(Berry & Walter, 2012; Louis J Elsas, 1993; Fridovich-Keil & Walter, 2013). In 
North Americans, the frequency of the Q188R allele is between 60-70% in 
individuals with galactosemia (Fridovich-Keil & Walter, 2013). 
The Duarte galactosemia variant is characterized by the substitution of an 
aspartate for an asparagine at the amino acid position 314 and is known as the 
N314D mutation (Louis J Elsas, 1993; Fernhoff, 2010; Ficicioglu et al., 2008). 
The Duarte allele actually exists in two different forms: Duarte-1 and Duarte-2 
(Louis J Elsas, 1993; Ficicioglu et al., 2008; Fridovich-Keil & Walter, 2013). While 
both forms of Duarte allele mutations exhibit the same amino acid substitution at 
position 314, the Duarte-2 allele also has a 4 base pair deletion. The Duarte-1 
allele, known as the Los Angeles variant, does not have the additional 4 base-
pair deletion, but rather a second L218L mutation and the GALT enzyme activity 
actually is elevated (Louis J Elsas, 1993; Ficicioglu et al., 2008; Fridovich-Keil & 
Walter, 2013). In Duarte-2 alleles where there is the 4 base-pair deletion on the 
promoter region, GALT enzyme activity is depressed (Louis J Elsas, 1993; 
Fernhoff, 2010). On average, the activity is 25% of normal (Berry & Walter, 2012; 
Louis J Elsas, 1993; Fernhoff, 2010; Ficicioglu et al., 2008; Fridovich-Keil & 
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Walter, 2013). In the United States population, the Duarte-2 variant mutation has 
about a 5% incidence, meaning 1 in 20 people carry this Duarte allele. When the 
Duarte-2 variant and a classic galactosemia mutation coexist on different alleles, 
the patient is diagnosed with Duarte galactosemia (L. J. Elsas et al., 1994; 
Ficicioglu et al., 2008; Fridovich-Keil & Walter, 2013).  
In the United States where newborn screening is widely used, the 
standard and primary method in screening for galactosemia is by a determination 
of the GALT enzyme activity and by analysis of total galactose and/or gal-1-P in 
the blood. Furthermore, GALT gene mutation analysis can also be obtained to 
assist the neonatal screening using patient DNA from a blood sample (Berry & 
Walter, 2012; Louis J Elsas, 1993; Fridovich-Keil & Walter, 2013). For classic 
galactosemia, the alleles that are most frequently seen and that are targeted for 
in gene mutation analysis are Q188R, S135L, K285N, and L195P (Louis J Elsas, 
1993; Ficicioglu et al., 2008; Fridovich-Keil & Walter, 2013). The S135L is a 
unique mutation of African origin where a serine is substituted for leucine at 
amino acid position 135. This mutation is mostly found in Africans and African-
Americans and has been found to account for 50% of the GALT allele mutations 
in African-Americans (Fridovich-Keil & Walter, 2013). For Duarte galactosemia, 
patients are screened for the N314D mutation (Louis J Elsas, 1993; Ficicioglu et 
al., 2008; Fridovich-Keil & Walter, 2013). 
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A Further Look at Long-Term Complications of Galactosemia: Known 
Neurodevelopmental Outcomes of Classic vs. Duarte Galactosemia 
 There have been numerous studies detailing the depths of the 
neurodevelopmental outcomes of a classic galactosemia diagnosis such as 
impaired intelligence quotients (IQ), problems with speech, and deficits in 
language development (Antshel, Epstein, & Waisbren, 2004; Nelson, 1991; 
Potter, Lazarus, Johnson, Steiner, & Shriberg, 2008; Ridel, Leslie, & Gilbert, 
2005; Schadewaldt et al., 2010; Schweitzer, Shin, Jakobs, & Brodehl, 1993; 
Waggoner, Buist, & Donnell, 1990; Waisbren et al., 1983).These patients have 
also been found to have tremors, small brain size, and ataxia or uncoordinated 
muscle movements (Schweitzer et al., 1993). There are also records of early 
intervention services in classic patients to assist in specific learning delays 
(Potter et al., 2008). Interestingly, these various neurodevelopmental outcomes 
have been found not to be associated with how early or how well the patient has 
been treated nor with the severity of the classic galactosemia disease (Antshel et 
al., 2004; Nelson, 1991; Schadewaldt et al., 2010; Schweitzer et al., 1993; 
Waisbren et al., 1983).  
Many studies have made evident that the severity and persistence of the 
cognitive impairments in IQ, speech, and language development can also vary 
across the classic galactosemia population (Potter et al., 2008). Sometimes 
classic galactosemia can result in near-normal or even normal mental ability in 
those less affected by the disease but can also result in a lifetime’s struggle due 
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to large mental disability in patients that are highly affected (Schadewaldt et al., 
2010). Still, all together the studies on the long-term outcomes of classic 
galactosemia indicate a relatively consistent profile of neurodevelopmental delay 
and intellectual deficits (Antshel et al., 2004).  
Compared to the vast amount of literature for the classic galactosemia 
population, only few studies have been conducted on the Duarte population and 
among those, even fewer on the long-term neurodevelopmental outcomes of the 
variant (Badik et al., 2011; Powell et al., 2009). Since Duarte patients are 
recognized in newborn screening programs, the question remains whether the 
reduced GALT enzyme activity is a risk factor for patients to acquire outcomes 
similar to those of classic galactosemia (Ficicioglu et al., 2008). There were 
strides in answering these questions when Ficicioglu and colleagues (2008) 
showed that their cohort of D/G patients had good and unaffected developmental 
outcomes whether or not they were treated with a diet in their first year of life 
(Ficicioglu et al., 2008). They found that even though untreated D/G patients had 
increased levels of metabolites due to galactose ingestion, those levels did not 
compare to levels seen in classic galactosemia and did not cause any 
developmental disability in early childhood. This was an indication that Duarte 
galactosemia metabolite levels may not be in a toxic range. Finally, neither group 
of D/G patients (treated or untreated) developed any symptoms associated with 
the classic form of galactosemia (Ficicioglu et al., 2008).  
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Contrary to the studies of Ficicioglu and colleagues (2008), Powell and 
colleagues (2009) found some indications of possible developmental problems in 
the Duarte galactosemia patients (Powell et al., 2009). They examined a 
population-based sample of school-age Duarte patients for long-term speech and 
language developmental problems that required special education services. They 
found that despite dietary treatment up to 1 year of age, there were in fact some 
developmental problems among some children with Duarte galactosemia. 
Speech and language problems were evident and the requirement of special 
education was higher for older children with this variant than for the general 
population (Powell et al., 2009). 
 
The Enigma of Duarte Galactosemia 
 While there have been steps towards examining the long-term outcomes 
of Duarte galactosemia, more studies are needed. Even though Ficicioglu and 
colleagues (2008) found no developmental delay in their Duarte cohort, they only 
examined patients from 1 to 6 years of age (Ficicioglu et al., 2008). On the other 
hand, Powell and colleagues (2009) did find developmental problems in their 
Duarte population but the significance appeared in older children and only the 
treated patients were examined (Powell et al., 2009). More examinations about 
how Duarte galactosemia patients compare to their classic counterparts may 
help more definitively point towards whether Duarte galactosemia can be 
characterized as a benign or more harmful disease. Studies that look at cognitive 
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development, language acquisition, motor ability and early intervention services 
in Duarte galactosemia patients over time can help increase the knowledge of 
delays regarding if and when they might arise. Even if Duarte patients may not 
be found to have deficits similar to the classic patients, perhaps they still exhibit 
developmental delays and learning complications compared to population norms. 
Finally, more studies to document any consistent future outcomes in untreated 
Duarte patients can help calm the debate of whether treatment is needed for a 
Duarte galactosemia diagnosis. 
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SPECIFIC AIMS AND OBJECTIVES 
 
 
This thesis aims to study and compare the mental development, 
intelligence quotients, and special developmental needs of Duarte galactosemia 
patients to the general population. The results will also be compared to a group 
of individuals with classic galactosemia. This study will examine any possible 
long-term neurodevelopmental outcomes among the Duarte galactosemia 
population within the context of the long-term complications in classic 
galactosemia. 
There are four study objectives that will help explore the cognitive 
development and possible neuropsychological complications of Duarte 
galactosemia patients seen for psychological evaluations during infancy, 
childhood, or adolescence.  
The first objective is to examine the mental development, intelligence 
quotients, and special developmental needs of Duarte patients compared to 
established population norms of children unaffected by disease. The goal is to 
determine if overall, Duarte patients might experience developmental delays and 
increased need for special services more often than unaffected children yet less 
than what is observed for the classic galactosemia control group.  
The second objective is to determine to what extent Duarte galactosemia 
patients might have other neurodevelopmental complications, such as the 
specific needs in early intervention and special education services. The goal is to 
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examine these complications and determine which services, if any, demonstrate 
a greater use. This may be an indication of common developmental problems 
within the Duarte galactosemia population. 
The third objective is to compare the cognitive and language development 
to the motor development in Duarte galactosemia patients during early infant and 
toddler years. The goal is to determine if there is an observed significance in the 
difference of these scores first within the Duarte population and then 
comparatively to the classic population. This can be an indication of the areas in 
development in which Duarte galactosemics start to excel or struggle. 
The final objective is to examine the cognitive development of the Duarte 
galactosemia group and compare these results to a group of individuals with 
classic galactosemia. The goal is to determine if Duarte patients exhibit a pattern 
of deficits similar to those in the classic galactosemia group, albeit to a lesser 
degree.  
Overall, this thesis attempts to complete a consistent profile for the long-
term outcomes of Duarte galactosemia and ventures to answer the larger 
question of whether Duarte galactosemia has any problems at all. 
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METHODS 
 
 
Participants 
 108 patient profiles were reviewed and examined in this study. These 
subjects were obtained from an entire sample of completed neuropsychological 
clinic visits at a university-affiliated outpatient metabolism clinic at Boston 
Children’s Hospital. The patients were seen from 1978 to 2013. The inclusion 
criteria were a confirmed diagnosis of either Duarte galactosemia, classic 
galactosemia, or other variant galactosemia and an IQ test or an infant 
developmental test.  
 
Procedure 
  The study conducted was a cross-sectional retrospective chart review. 
The convenience cohort of actual patient clinical charts derived from 
neurodevelopmental psychological evaluations was reviewed. The outcome 
variables collected from the review included demographic information, baseline 
diagnosis information, and scores on developmental tests, as well as reports of 
early intervention services, developmental delay or special education services.  
A database was created to suit the needs for the information collected in 
this study. For every subject, information available in the clinical charts was 
recorded. Type of galactosemia, diet, and genotype were recorded under 
diagnosis information. Genotype was collected for the classic or other variant 
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galactosemia diagnosis if available in the chart. For the primary study group of 
Duarte galactosemia patients, the genotypes were also recorded by further 
examination in hospital electronic records.  
Other neuropsychological outcomes were recorded once for each subject 
of the review if available. These outcomes included early intervention services, 
special education services, age at which services started, any noted signs of 
autism or attention deficit disorder, and tremors. Early intervention services were 
any therapies or other developmental assistance used by patients from birth until 
the age of 3. Special education services were the same such therapies or other 
developmental and academic assistance used by patients greater than age 3 at 
which they are entering school-attending age. The specific types of services used 
were also recorded if subjects were documented to participate in early 
intervention and/or special education. All of these outcomes were put into the 
database if recorded in visit reports or included by parent or patient report. 
For the neurodevelopmental battery of the subjects, all subjects of the 
study had at least one evaluation but some subjects had more than one 
neurodevelopmental or psychological evaluation. For each visit, the age at which 
the examination was performed was recorded as well as the resultant scores of 
the developmental or IQ tests of the visit. Each evaluation included had either an 
infant test for cognitive, language, and/or motor ability or a test for intelligence 
that included a verbal comprehension, perceptual performance, and/or full scale 
intelligence score. Other tests that may have been in the clinical chart, but that 
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were not required for the database, were behavioral and adaptive skills 
assessments and visual-motor integration tests. These scores, if available, were 
also entered into the database if they were present during an evaluation with 
intelligence tests for completeness of the chart review.  
The largest amount of data on neurodevelopmental tests that was attained 
were scores from the Bayley Scales of Infant Development, either the Second or 
Third Edition (Bayley, 1993, 2006). The Bayley Scales of Infant Development 
Second Edition provides a Mental Developmental Index (MDI) and a 
Psychomotor Developmental Index (PDI) (Bayley, 1993). The Bayley Scales of 
Infant Development Third Edition provides a Cognitive composite score, a 
Language composite score, and Motor composite score (Bayley, 2006). For 
purposes of this study, the MDI and Cognitive composite score were used to 
describe the overall developmental level, referred to as a Developmental 
Quotient or DQ. This has a mean of 100 and a standard deviation of 15 (Bayley, 
2006). The PDI and Motor composite score were also examined together. This 
also has a mean of 100 and a standard deviation of 15 (Bayley, 2006). Test 
scores from before the age of 1 year and test scores at an age equal to or after 1 
year were examined separately as age groups within each diagnosis.  
For developmental tests beyond the Bayley Scales of Infant Development, 
the tests that were performed within the Duarte group were the Wechsler 
Preschool and Primary Scale of Intelligence (Wechsler, 2002), the Wechsler 
Intelligence Scale for Children, Third or Fourth Edition depending on what 
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version was most current at the time of testing (Wechsler, 1991, 2003), or the 
Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999). These tests 
provide a Verbal Comprehension score, a Perceptual Performance Score, and a 
Full Scale IQ score. These have a mean of 100 and a standard deviation of 15 
(Wechsler, 2003).  
Exclusion criteria included subjects in which no intelligence or mental 
developmental tests were found as well as individual visits within subject profiles 
without intelligence or mental developmental tests. Subject charts were reviewed 
for history of any significant, yet unrelated, medical problems that might influence 
the performance in their evaluation but none were found to have any other 
condition. This retrospective chart review was performed with the approval of the 
Boston Children’s Hospital Institutional Review Board (IRB-P00010681). 
 
Statistical Analysis 
 The data analysis for this study used the SPSS statistics program (IBM 
SPSS Statistics Version 21) along with an in-depth non-program analysis and 
discussion of the data collected. Trends, points of interests, and tests for 
statistical significance comparing Duarte patients to the general population norms 
and to the classic galactosemia group were the specific aims of the data 
analysis. Descriptive statistics of the subject population as well as of the outcome 
variables collected were attained. 
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The distribution of the outcome variables were examined using 
histograms, box-plots, and tests for normality. Special services needs for the 
Duarte study group were examined in comparison to the population values of 
such services. Sex, diet, developmental problems, and neuropsychological 
complications such as early intervention and special services between the study 
groups were further examined using chi-squared analyses.  
Cognitive developmental differences between the Duarte study group and 
classic galactosemia group were compared using their means and standard 
deviations. To account for the small number of patients in which repeated 
measures were attained, the average of developmental scores from either infant 
or IQ tests for those patients with more than one examination was used. Tests 
were also performed using all scores instead of averages and no difference or 
change in significance was found. The results remained the same. Because the 
majority of the subjects in the study presented with at least an infant test for 
development, infant test scores from before 1 year of age and infant test scores 
at 1 year of age or older were described separately as age groups within each 
diagnosis for some analyses. To examine the differences between cognitive 
and/or language developmental scores versus motor development scores within 
test groups, t-tests for paired samples were used where data had normal 
distribution. Wilcoxon Signed-Rank tests for paired samples were used where 
data sets had non-normal distribution. Independent samples t-tests were used to 
compare infant tests scores between age groups before and after 1 year old for 
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the Duarte and classic galactosemia populations where data followed a normal 
distribution and Mann-Whitney U independent samples tests were used for data 
that were of non-normal distribution. 
While data were collected for all patients in the convenience sample that 
had some form of galactosemia, those with some other variant form of the 
disease were not considered in the formal analysis. The reasons for this are that 
the Duarte galactosemia patients were the primary group of the study, the classic 
galactosemia patients represented a control group, and the other variant group 
had a very small sample size and was less homogenous. 
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RESULTS 
 
 
Description of the Study Sample 
 Among the 108 study subjects, there were 22 patients diagnosed with 
Duarte galactosemia, 73 patients diagnosed with classic galactosemia, and 13 
patients diagnosed with some other variant form of galactosemia. There were 3 
clinical charts reviewed but excluded from the study since these charts were 
found without any developmental tests—2 patients were diagnosed with classic 
galactosemia and 1 patient was diagnosed with Duarte galactosemia. The 
patients ranged in age from 6 months to 40 years at the time of their visit or 
visits. Table 1 depicts the counts of males, females, and diets followed within the 
Duarte and classic galactosemia groups. Among the 22 Duarte galactosemia 
patients, there were 9 (40.9%) males and 13 (59.1%) females. Within the 73 
classic galactosemia patients, there were 39 (53.4%) males and 34 (46.6%) 
females. There was no significant difference between the number of males and 
females within the Duarte or classic galactosemia groups.   
In regards to diet history, 4 (18.2%) of the 22 Duarte galactosemia 
patients were recorded to be on a galactose-restricted diet at the time of the 
examination. However, 2 of the 4 patients on a galactose-restricted diet were on 
such a diet because of milk allergies or lactose intolerance and not because of 
their Duarte galactosemia diagnosis. There were 15 (68.2%) Duarte 
galactosemia patients recorded to have never been on a galactose-restricted diet 
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while 3 (13.6%) Duarte galactosemia patients were on a galactose-restricted diet 
for only a brief time of their lives. In the classic galactosemia group, 72 (98.6%) 
of these patients were on a galactose-restricted diet, 1 of which was on a true 
galactose-free diet and was strictly restricted from all lactose-containing foods 
including fruits and vegetables with the sugar. Only 1 (1.4%) classic 
galactosemia patient was recorded to be on a galactose-restricted diet briefly.   
Within the Duarte galactosemia cohort, 20 (90.9%) patients were found to 
have a heterozygous genotype with one Duarte gene and one classic 
galactosemia gene for a genotype of N314D/Q188R. There was 1 (4.5%) patient 
with a different heterozygous genotype of one Duarte gene and one African-
American galactosemia gene described as N314D/S135L. Lastly, 1 (4.5%) 
patient included in this group had a homozygous Duarte genotype described as 
N314D/N314D.  
Table 1 Basic Description of Study Sample  
Diagnosis    Diet History 
 N Male Female On Diet On Diet 
Briefly 
Never 
on Diet 
Duarte 
Galactosemia  
22 9 
40.9% 
13 
59.1% 
4 
18.2% 
3 
13.6% 
15 
68.2% 
 
Classic 
Galactosemia 
73 39 
53.4% 
34 
46.6% 
72 
98.6% 
1 
1.4% 
0 
 
Special Services: Early Intervention 
 Table 2 shows how many patients needed early intervention in the Duarte 
and classic galactosemia groups. Early intervention services were any therapies 
or other developmental assistance used by patients from birth until the age of 3. 
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In the Duarte galactosemia cohort, 18 of the 22 patients contained recorded 
information regarding the participation or non-participation of early intervention 
services. Of those 18 Duarte galactosemia patients, 7 (38.9%) patients confirmed 
participation in early intervention services and 11 (61.1%) patients did not use 
these services. Among the 7 patients that participated in early intervention, 2 
patients were on a galactose-restricted diet, 2 patients were on a diet for a brief 
time in their lives, and 3 patients were never on a diet. Among the 11 patients 
that did not participate in early intervention, 1 patient recorded to be on a diet and 
1 patient recorded to be on a diet briefly.  
In the classic galactosemia group, 51 patients were known to either 
participate or not participate in early intervention services. Among those 51 
classic galactosemia patients, 37 (72.5%) patients confirmed participation in 
early intervention services while 14 (27.5%) patients did not use these services. 
All 37 classic patients that participated in early intervention were on a galactose-
restricted diet.  
In a chi-squared analysis for diagnosis and early intervention, it was found 
that disease and early intervention variables were significantly dependent 
(p=0.005). There were less Duarte galactosemia patients participating in early 
intervention and more classic galactosemia patients participating in early 
intervention than would be expected if early intervention and disease group were 
not correlated.  
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Table 2 also illustrates what services were used for those participating in 
early intervention within the Duarte and classic galactosemia groups. Among the 
7 Duarte patients that used early intervention services, the number of patients 
exceeded 40% in all categories of the type of early intervention used. Speech 
therapy was the most frequent type of early intervention used as 5 (71.4%) of the 
7 Duarte patients in early intervention needed it for speech. This is comparable to 
the percentage of classic galactosemia patients where 26 (70.3%) of 37 classic 
patients were in early intervention for speech therapy. The next frequent type of 
early intervention used in the Duarte group was physical therapy where 4 
(57.1%) of the 7 Duarte patients used it. Only 10 (27%) of the 37 classic patients 
in early intervention used physical therapy. For occupational therapy or other 
developmental therapy, 3 (42.9%) of the 7 Duarte patients were recorded in each 
these services. For the classic group, 14 (37.8%) of the 37 and 11 (29.7%) of the 
37 classic patients in early intervention used occupational therapy and other 
developmental therapy respectively.  
Table 2 Early Intervention Needs for Duarte Galactosemia and Classic Galactosemia. 
Early Intervention 
 Yes No Total 
Duarte Galactosemia 
 
7 
38.9% 
11 
61.1% 
18 
 
Speech 5 
71.4% 
  
Physical Therapy 4 
57.1% 
  
Occupational Therapy 3 
42.9% 
  
Other 3 
42.9% 
  
Classic Galactosemia 37 
72.5% 
14 
27.5% 
51 
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Speech 26 
70.3% 
  
Physical Therapy 10 
27% 
  
Occupational Therapy 14 
37.8% 
  
Other 11 
29.7% 
  
Note: count and percentages for each type of service calculated from the count of “yes” to early 
intervention. 
 
Special Services: Special Education 
Table 3 presents the numbers of patients in special education within the 
Duarte and classic galactosemia groups. Special education services were any 
therapies or other developmental and academic assistance used by patients 
greater than age 3 at which they are entering school-attending age. For the 
Duarte patients, 18 of the 22 subjects were known to either have participated or 
not participated in special education. Of those 18 patients, 4 (22.2%) participated 
in special education services while 14 (77.8%) did not. Among the 4 patients that 
participated in special education, 2 were recorded to be on a diet while the other 
2 were never on a diet.  
In the classic galactosemia group, 57 patients contained known 
information regarding the use of special education services. Among those 57 
classic galactosemia patients, 43 (75.4%) patients were recorded to have 
participated in special education and 14 (24.6%) patients did not. All but one of 
the 43 classic patients that had special education were on a diet. The one that 
was not on a diet at the time of the visit had been on a diet previously. 
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In a chi-squared analysis for diagnosis and special education, it was found 
that the two variables were also significantly dependent (p<0.001). There were 
less Duarte galactosemia patients in special education and more classic 
galactosemia patients in special education than would be expected if special 
education and disease group were not correlated.  
Table 3 also demonstrates the specific services used for special education 
among the Duarte and classic galactosemia groups. Within the Duarte cohort, 
those found to participate in special education and the resulting types of special 
education decreased to 4 patients. Among those 4 patients, all (100%) of them 
participated in special education services for speech. These means that 4 
(22.2%) of the 18 Duarte patients whose participation in special education 
services was known needed speech therapy. In the classic group, 35 (81.4%) of 
the 43 classic patients partook in special education services for speech. For 
special education services in physical therapy and occupational therapy, only 1 
of the 4 and 2 of the 4 Duarte patients in special education used physical and 
occupational therapy. In the classic group, there were 15 (34.9%) and 26 (60.5%) 
of the 43 classic patients in special education that needed physical and 
occupational therapy. Finally, none of the Duarte galactosemia patients in special 
education required any special services for academic problems. In comparison, 
25 (58.1%) of the 43 classic galactosemia patients required special education for 
academic problems. 
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Table 3 Special Education Needs for Duarte Galactosemia and Classic Galactosemia 
Special Education 
 Yes No Total 
Duarte Galactosemia 
 
4 
22.2% 
14 
77.8% 
18 
Speech 4 
100% 
  
Physical Therapy 1 
25% 
  
Occupational Therapy 2 
50% 
  
Other (Academics) 0 
 
  
Classic Galactosemia 43 
75.4% 
14 
24.6% 
57 
Speech 35 
81.4% 
  
Physical Therapy 15 
34.9% 
  
Occupational Therapy 26 
60.5% 
  
Other (Academics) 25 
58.1% 
  
Note: count and percentages for each type of service calculated from the count of “yes” to special 
education. 
 
Developmental Testing Outcomes 
 For Bayley Scales of Infant Development, the Cognitive/MDI score 
distributions were found to be non-normal and thus non-parametric tests were 
used for any analysis involving cognitive/MDI scores. The language and 
motor/PDI scores were found to have normal distribution. 
Table 4 describes the Bayley scores from before 1 year of age and from 
equal to or after 1 year of age for the Duarte galactosemia patients. There were 
19 of 22 Duarte patients that had at least one recorded Bayley test. Some of 
these Bayley tests were given prior to the age of 1 and some at or after the age 
of 1. At the age of less than 1 year, the mean cognitive/MDI score was 109.5 
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(Standard deviation (SD) =6.26; n=8), the mean language score was 105.57 
(SD=12.18; n=7), and the mean motor/PDI score was 98.25 (SD=12.54; n=8). At 
the age of greater than or equal to 1 year, the Duarte galactosemia cohort 
presented with a mean cognitive/MDI score of 108.74 (SD=13.95; n=15), a mean 
language score of 104.5 (SD=15.81; n=12), and a mean motor/PDI score of 
100.58 (SD=18.69; n=15). Overall, the scores from the Duarte patients were 
within average range of the Bayley Scales of Infant Development demonstrating 
no problems in early developmental testing. 
Table 4 Bayley Scales of Infant Development: Duarte Galactosemia 
Average Bayley Scales of Infant Development scores for the Duarte cohort before 1 year of age 
and equal to or after 1 year of age.  
Duarte Galactosemia n Mean Standard 
Deviation 
Cognitive/MDI                            Age <1 
                                                   Age ≥ 1 
8 
15 
109.50 
108.74 
6.26 
13.95 
Language                                   Age <1 
                                                   Age ≥ 1 
7 
12 
105.57 
104.50 
12.18 
15.81 
Motor/PDI                                   Age <1 
                                                   Age ≥ 1 
8 
15 
98.25 
100.58 
12.54 
18.69 
 
 Table 5 describes the Bayley scores from before 1 year of age and from 
equal to or after 1 year of age in the classic galactosemia group. There were 44 
of the 73 classic patients that had at least one recorded Bayley test. Some of 
these tests were given prior to the age of 1 year and some given at equal to or 
after the age of 1 year. For the age of less than 1 year, the mean cognitive/MDI 
score was 106.32 (SD=16.38; n=28), the mean language score was 111.4 
(SD=19.58; n=5), and the mean motor/PDI score 96.48 (SD=18.52; n=25). For 
the classic galactosemia group at an age of greater than or equal to 1 year, the 
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mean cognitive/MDI score was 98.33 (SD=16.58; n=35); the mean language 
score was 99.92 (SD=12.55; n=12), and the mean motor/PDI score was 97.34 
(SD=20.22; n=26). 
Table 5 Bayley Scales of Infant Development: Classic Galactosemia 
Average Bayley Scales of Infant Development scores for the classic cohort before 1 year of age 
and equal to or after 1 year of age.  
Classic Galactosemia n Mean Standard 
Deviation 
Cognitive/MDI                             Age <1 
                                                    Age ≥ 1 
28 
35 
106.32 
98.33 
16.38 
16.58 
Language                                    Age <1 
                                                    Age ≥ 1 
5 
12 
111.40 
99.92 
19.58 
12.55 
Motor/PDI                                    Age <1 
                                                    Age ≥ 1 
25 
26 
96.48 
97.34 
18.52 
20.22 
 
 A longitudinal analysis was done for the disease groups to compare the 
differences in the scores from before 1 year old to scores equal to or after 1 year 
old. For the cognitive/MDI scores, the Mann-Whitney U tests for the separate age 
groups were used. There was no significance difference in the Duarte 
galactosemia group between the cognitive/MDI scores from before 1 year and 
equal to or after 1 year of age. There was a significance difference in the classic 
galactosemia group between the cognitive/MDI scores from before 1 year and 
equal to or after 1 year of age (p=0.028). For the language and motor/PDI 
scores, comparisons of the differences between these scores before and equal 
to or after 1 year of age were found using independent samples t-tests. In both 
the Duarte and classic groups, there was no significant difference between the 
language scores or between the motor scores before and equal to or after the 
age of 1. 
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Paired comparisons within the disease groups were also performed to 
examine the differences between cognitive/MDI scores versus motor/PDI scores 
as well as language scores versus motor/PDI scores. These comparisons were 
separated at age before 1 and at age equal to or after 1. To compare the 
cognitive/MDI and motor/PDI scores, Wilcoxon Signed-Rank tests for paired 
samples were used. Paired-samples t-tests were used for the language and 
motor/PDI comparisons. In the Duarte group, there existed a significance 
difference between the cognitive/MDI score and the motor/PDI score at an age 
less than 1 (p=0.028). This was the same for the classic galactosemia group 
(p<0.001). The cognitive/MDI mean scores were 11.25 (Duarte) and 9.84 
(classic) points higher than the motor/PDI mean scores. There was no significant 
difference between the language and motor/PDI scores for the Duarte or the 
classic groups at the age of less than 1.  
At an age equal to or greater than 1, the Duarte group continued to show 
a significant difference between the cognitive/MDI score and the motor/PDI score 
(p=0.017). The cognitive/MDI mean score was 8.16 points higher than the 
motor/PDI mean score. However, there was no longer a significant difference 
between the cognitive/MDI and motor/PDI scores within the classic group at an 
age equal to or greater than 1. The difference between the cognitive/MDI and 
motor/PDI mean scores in this age group for the classic cohort was just 0.99. In 
both the Duarte and classic groups, there remained no significant difference 
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between the language and motor/PDI scores at the age of greater than or equal 
to 1.  
For developmental tests beyond the Bayley Scales of Infant Development, 
6 Duarte galactosemia patients had an IQ test. As noted in Table 6, the mean 
verbal comprehension score was 109.11 (SD=11.39; n=6), the mean perceptual 
performance score was 112.45 (SD=10.49; n=6), and the mean full scale score 
was 111.4 (SD=11.99; n=5). The Duarte patients’ scores were within average 
range of normal values. 
Table 6 Intelligence Quotient Scores: Duarte Galactosemia 
Average verbal comprehension, perceptual performance, and full scale IQ scores for the Duarte 
cohort. 
 n Mean Standard Deviation 
Verbal Comprehension 6 109.11 11.39 
Perceptual Performance 6 112.45 10.49 
Full Scale 5 111.40 11.99 
 
“Any” Developmental Outcomes and Diet 
 Within the Duarte cohort, a variable was created using the data to 
examine whether any developmental problem was associated with an adherence 
to a diet at any point in life. Duarte patients in this study were separated into a 
group for any developmental problem based on whether they had at least one of 
the following: early intervention, special education, or a difference of at least +10 
between the average cognitive/MDI and motor/PDI score either before or after 
the age of 1. Table 7 presents the number of Duarte patients with any 
developmental problem cross-tabulated with diet history. It was found that 6 
(85.7%) of the 7 Duarte subjects recorded to either have been on a diet or were 
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currently on a diet fell under the category of having any developmental problem. 
Of the 15 Duarte patients that were never on a diet, 7 (46.67%) patients were 
also found to have one of the developmental problems. Upon chi-square 
analysis, the variables of diet and any developmental problem were found not 
independent and not significant. 
Table 7 Any Developmental Problem and Diet in the Duarte Cohort 
Duarte subjects with early intervention, special education, or 10 point difference between 
cognitive/MDI and motor/PDI score cross-tabulated by diet. 
 Any Developmental Problem 
Total 
Has either early intervention, 
special education or at least 10 
point difference between 
Cognitive/MDI and Motor/PDI 
Has no 
problem 
 
Diet On diet currently 
or at some point 
6 
85.71% 
1 
14.29% 
7 
100% 
Never on diet 7 
46.67% 
8 
53.33% 
15 
100% 
Total 13 
59.09% 
9 
40.91% 
22 
100% 
 
Indications of Speech or Language Problems in the Duarte Galactosemia 
Cohort 
 Since speech therapy is the most prevalent service used among the 
Duarte population, a closer examination was performed on the data with a focus 
on any complications in speech or language. As mentioned above, there were 
records of Duarte patients that had speech therapy in early intervention or 
special education. However, there were also Duarte patients with other chart 
findings in relation to speech and language, such as speech and language skills 
that were less developed than cognitive or motor skills. In total, 11 (50%) of the 
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22 Duarte patients had either speech therapy or a chart note expressing that the 
speech or language skills were less developed at the time of testing. Among the 
11 patients, 4 patients did not have speech therapy but did have lower language 
scores and a note of less-developed speech and language skills in comparison to 
their cognitive and motor skills. Developmental testing showed all the scores 
were within average range, but that the language score fell lower in the average 
range. The remaining 7 patients had speech therapy and corresponding speech 
and language difficulties or delays in the chart notes, with the exception of one 
who was noted to have very well developed language skills. Additionally, 4 of the 
11 patients had a diet history and 7 patients were never on a diet. 
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DISCUSSION 
 
 
 In the cohort of Duarte galactosemia patients, the results were both 
surprising in certain areas and consistent with prior literature in other areas. In 
the primary study group, the Duarte galactosemia patients were found not to 
show decline in their developmental scores. For the Bayley Scales of Infant 
Development, none of the scales in this test fell below 98.25. This was the mean 
motor/PDI score for Duarte subjects before the age of 1. Even so, the 
cognitive/MDI and language scores before and equal to or after 1 year of age as 
well as the motor/PDI score equal to or after 1 year of age were at least 100. At 
older ages in which subjects were given IQ tests, the mean verbal 
comprehension, perceptual performance, and full scale scores were each over 
108, well within average range. Ficicioglu et al (2008) found that their Duarte 
subjects all had normal range developmental quotients (Ficicioglu et al., 2008). 
While the findings in this study are consistent with the study by Ficicioglu et al 
(2008) it remains difficult to discern a developmental problem solely from these 
test scores. The test scores used suggest normal development but, since the 
majority of the test scores were performed at a very early age, they may not be 
an accurate reflection of the complete neurological development in these 
patients. Some Duarte patients in this study did have intelligence tests at an 
older age. However, with the small Duarte sample in this study and even fewer of 
that sample with developmental tests at an older age, it is still difficult to 
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definitively eliminate any developmental problems based on all the test scores 
alone. 
The classic group had results similar to previous studies. To summarize, 
the classic group was found to have high incidences of early intervention and 
special education. There was need for speech therapy both early in development 
as well as later in the school-age years. This corroborates past findings indicating 
that classic galactosemia patients are at a higher risk for speech and language 
disorders throughout childhood, adolescence, and adulthood (Hoffmann, Wendel, 
& Schweitzer-Krantz, 2011; Potter et al., 2008; Ridel et al., 2005; Waisbren et al., 
1983). The classic galactosemia patients in this study also experienced declines, 
even early on, in developmental quotients after 1 year of age. The motor/PDI 
scores in the classic galactosemia toddler years remained under 100 before and 
after 1 year of age and their cognitive and language scores followed suit in tests 
after 1 year of age. In intelligence tests at older ages, the classic group had a 
majority of low verbal comprehension (mean of 85.21±17.16), perceptual 
performance (mean of 86.25±18.36), and full scale scores (mean of 85.21±19) 
but showed some variability. Finally, these results were found despite the 
adherence to a galactose-restricted diet. These cognitive findings are consistent 
with previous studies documenting cognitive impairment and generalized 
reduced IQ (Antshel et al., 2004; Nelson, 1991; Ridel et al., 2005; Schadewaldt 
et al., 2010; Waggoner et al., 1990).  
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Comparing the infant scores of the Duarte group to the classic group, it 
was interesting to see the longitudinal differences before a year old and after a 
year old. Both the Duarte cohort and classic group had similar significant 
differences between the mean cognitive scores and mean motor scores before 1 
year of age. However, once patients were 1 year old or after, the classic 
galactosemia group started to separate as expected. They now had cognitive 
and motor scores that were lower overall and the cognitive and motor scores 
were no longer significantly different. The Duarte group still had significantly 
higher cognitive scores than motor scores. This suggests that based on 
developmental tests, the Duarte group develops consistently in early infancy and 
toddler years and does not show declines in development like the classic group. 
Again, at the young age in which these tests are performed, the scores are 
subject to variability and may be unable to depict learning problems. Taken all 
together, it remains difficult to distinguish issues in development just from these 
test scores. 
The study results did, however, depict some possible developmental 
issues in Duarte galactosemia patients from the information acquired of the need 
and use of special services, such as early intervention and special education. 
Powell et al (2009) found in their study that a high percentage of Duarte 
galactosemia patients in the Atlanta, Georgia area were receiving special 
education, particularly for speech and language disorders (Powell et al., 2009). 
When they restricted their study to subjects of age 8, they found that the 
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percentage of Duarte subjects receiving special education was 2.5 times that of 
the general population in Atlanta (Powell et al., 2009). Similar to the study by 
Powell et al (2009), this study also found high percentages in special services but 
in the use of both early intervention services and special education services. 
Where participation in early intervention was known, almost 40% of the Duarte 
patients were confirmed for these services. Among those patients, the majority of 
them (71%) needed speech therapy and greater than 40% required physical 
therapy, occupational therapy, or other help during their infant and toddler years. 
A high percentage of the Duarte patients were also confirmed to 
participate in special education. While the number of patients in special 
education was below that for early intervention (22%), it was found that some 
learning problems still existed as these patients reached school age. There was 
less of a need for physical therapy and occupational therapy as well as no need 
for academic help. However, what is remarkable among the Duarte patients in 
special education is that all (100%) of them were in speech therapy. This 
suggests that the need for speech therapy remained high throughout the infant 
and toddler ages to school-attending ages in this Duarte population. Even though 
developmental testing indicated consistent cognitive development, these data on 
early intervention and special education show that developmental problems may 
have been masked by the within-average test scores.  
Compared to the general population, the findings of special services for 
the Duarte population in this study are striking. While the chi-squared analysis 
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showed that Duarte patients were expected to participate less in these services 
due to their milder disease form compared to the classic patients, there was no 
indication that the Duarte patients needed the services less than the unaffected 
population. Perhaps the correlation indicates a developmental problem in the 
Duarte population that is less severe than the classic group but existent 
nonetheless. A recent report found that 2.4% of infants and toddlers in the 
general population were reported to receive early intervention services 
(Blackorby et al., 2010). This study showed that the Duarte group exhibited much 
higher percentages than 2.4% in early intervention. The same report found that 
12.9% of school-age children in the general population receive special education 
(Blackorby et al., 2010). This study showed again that the percentage of Duarte 
patients in special education remained higher than the general population. With 
such a rare disease and a resultant small sample size, it was difficult to make 
statistical conclusions as to whether the prevalence of services in this Duarte 
population was higher than what would have been expected by chance among 
the national population. However, the findings are described and discussed 
compared to found population percentages and are consistent with the findings 
by Powell et al (2009)—more Duarte patients used special services compared to 
the general population. Therefore, this study suggests Duarte galactosemia 
patients exhibit an increased need of special services compared to those children 
of the general population. Developmental problems in Duarte galactosemia may 
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be more evident in the education services that are used rather than the test 
scores that are attained.  
Classic galactosemia patients are known to be at risk for speech delays 
and language impairments (Hoffmann et al., 2011; Potter et al., 2008; Ridel et al., 
2005; Waisbren et al., 1983). Among the general population, there is 8-9% 
prevalence of speech and language disorders (“Quick Stats for Voice, Speech, 
and Language [NIDCD Health Information],” 2010). In this study, the proportion 
of Duarte patients in speech therapy was high. It was found that 5 (27.8%) of the 
18 Duarte patients whose information regarding early intervention was known 
needed speech therapy and 4 (22.2%) of the 18 Duarte patients whose 
information regarding special education was known needed speech therapy. The 
patients needing speech therapy had recorded notes of speech and language 
difficulties and/or delays. Compared to the national percentage, the prevalence of 
speech therapy in this study suggests that the percentage of Duarte 
galactosemia patients with speech and language disorders is about 3 times 
higher than the general population. Thus, there may be developmental problems 
particularly in the areas of speech and language for Duarte galactosemia 
patients. This problem may not be similar in severity to the classic group but can 
be a significant problem in comparison to children without this disease.  
Furthermore, the data suggest that speech problems may arise during the 
infant and toddler years for Duarte galactosemia patients but that these problems 
do not appear to be coupled with an overall intelligence test decline like the 
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classic galactosemia counterparts. There were Duarte patients in this study 
which did not have speech therapy but had Bayley language scores that were 
less-developed compared to the other areas of measurement yet still within an 
average range. Hence, not only may Duarte patients experience some delays in 
the speech and language area, but these delays may be evident early in 
development and despite normal range test scores. 
Lastly, diet therapy for the Duarte cohort continues to remain puzzling in 
its positive or negative effects. The Duarte patients that were found to have 
developmental problems or less-developed speech or language were those with 
and without a diet. There was no indication or statistical significance that diet 
correlated with a developmental outcome or special service. This study is unable 
to determine if diet affected the use of services or developmental scores.  
One limitation of this study was the small sample size of Duarte 
galactosemia patients from the convenience sample of patient charts. Since this 
study relied on the patient files among a stored record of neuropsychological or 
developmental testing, it is possible that Duarte patients whose charts were 
never placed in these files were missed. Another limitation to this study was that 
the review was limited to what was available within the clinical charts. Therefore, 
it was difficult to discern if the Duarte patients had other reports or 
measurements regarding any developmental history prior to their visits. An 
inclusion bias was a limitation of this study. Since the review was from a 
convenience sample of charts, it is possible that these patients only came into 
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the metabolism clinic because they already showed problems. Other patients 
might have come in only because of a suggestion from their pediatrician and 
were otherwise fine after just one examination. Classic patients typically undergo 
neuropsychological evaluations because of the high risk of developmental 
problems. Thus, it is possible that some Duarte patients might have come in after 
parents learned of the outcomes of classic galactosemia and wanted to confirm 
that their Duarte child did not have similar symptoms. Finally, there were no 
siblings of Duarte galactosemia patients with homozygous normal alleles among 
the convenience cohort that could have represented a normal control group.  
Despite these limitations however, this study did have important strengths. 
The test results and clinic reports of the Duarte population were from actual in-
person psychological evaluations. The visits involved conversations between 
patients and their guardians and the senior psychologist. Patient testing, test 
results and visit evaluations were performed, tabulated and reported by the 
senior psychologist. Consequently, this study was able to gather valuable data 
among the Duarte cohort and a beneficial database was created for Duarte 
galactosemia patients. Furthermore, a compilation of certain outcomes within the 
Duarte population provided an opportunity to examine the Duarte patients as a 
whole.   
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CONCLUSION 
 
 
Most of the patients found to have the Duarte form of galactosemia often 
do not show any clinical signs of a disease and many specialists in the metabolic 
field believe that Duarte galactosemia is not a disease entity (Berry & Walter, 
2012; Louis J Elsas, 1993; Ficicioglu et al., 2008; Fridovich-Keil & Walter, 2013). 
This study found some developmental problems in the Duarte population in the 
areas of the need for special services. While the Duarte group did not experience 
large deficits in the test scores compared to their classic counterparts, they did 
demonstrate the need for help and therapies in early infant and toddler ages as 
well as when they were of school-attending age. The severity of the long-term 
outcomes does not seem to match those of the classic galactosemia patients. 
Yet, the Duarte group showed a higher incidence in both early intervention and 
special education than the general population, particularly in the area of speech 
therapy. Thus, the Duarte galactosemia population appears to be at a higher risk 
for speech and language problems compared to a child without the disorder. 
Additionally, this study also showed no evidence that the use of diet-therapy for 
this group prevented problems. Treating a Duarte galactosemia patient did not 
prevent any need for special services but not treating a Duarte patient did not 
result in not needing those services either.  
These findings challenge the belief that Duarte galactosemia is a benign 
disease. Consequently, a continuation of routine examinations for Duarte 
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patients may need to be implemented to more closely monitor these patients. 
Future studies involving a larger sample size of Duarte galactosemia patients 
would provide more insight to the network of possible problems that these 
patients may experience throughout life. Additionally, an effort to study the adult 
population of Duarte galactosemia would be a worthwhile study objective since a 
large number of unstudied Duarte patients may now be adults. Finally, a long-
term prospective study can further confirm the prevalence of developmental 
problems and when they arise. This would help determine whether Duarte 
galactosemia patients can be expected to adapt to the problems, will continue to 
need services, or are at risk for other problems in behavior and socialization. 
Ultimately, it can help provide a more definitive consensus about the perplexing 
issues in Duarte galactosemia. 
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